Skip to content
Menu

Clearmind Medicine Publishes Hong Kong Patent Application Covering Innovative Psychedelic Compounds Targeting Treatment Of PTSD And Other Mental Health Disorders

Benzinga Newsdesk 1 day ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

The patent application is part of the Company's exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem ("Yissum"). The compounds were invented by Professors Ahmed Masaewa, Rami Yaka, and Avi Priel of the Hebrew University. Under the licensing agreement, Clearmind holds exclusive global rights to develop, manufacture, and commercialize the novel compounds.

The Hong Kong patent publication expands Clearmind's global patent application portfolio for its proprietary PTSD-focused psychedelic compounds. Together with existing international filings, the application supports the Company's strategy to seek intellectual property protection for its novel therapeutic candidates across major global markets.

Read at benzinga.com